Our CRISPR screen identified that drivers of ERα signaling remained essential for the viability of ER+ breast cancer cells irrespective of RB1 status (Fig. 1B), suggesting that ER+/RB-deficient breast cancer cells may still be dependent on ERα signaling. The gene discussed is RB1; the disease is breast carcinoma.